| Neoplasm of Uncertain Histogenesis altered in cohorts of …ALTERED_INderived200 of 956show all (up to 200) |
|---|
| ← altered in cohorts of | FAM189B 276 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DCST2 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA1 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MTX1 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB7B 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF2 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPM3 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA4 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDC4 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 3 cohorts | — | — | Hepatocellular Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | KRTCAP2 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LENEP 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC1 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRATD2 134 / 185 cases (72 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CKS1B 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DAP3 273 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 3 cohorts | — | — | Hepatocellular Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PYGO2 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RXFP4 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SHC1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC27A3 273 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LMNA 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MEX3A 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMVK 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDKN2B 133 / 185 cases (72 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BMP1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCT3 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV3L 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GATAD2B 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ISG20L2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMTOR2 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC71 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MNDA 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NTRK1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIWIL2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMF1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POLR3D 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB25 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEMA4A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D2A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SSR2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM79 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF10A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBE2Q1 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | UBQLN4 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAM28 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP30 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ATF6 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CRABP2 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV3 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3B 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GLMP 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HAPLN2 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HDGF 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NIT1 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OR6Y1 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAQR6 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | REEP4 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SNAPIN 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | USP21 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC6 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OC90 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLA 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYRIB 131 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ST3GAL1 131 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM71 131 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WASHC5 131 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF572 131 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTRT3 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BCHE 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC31 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRIQ4 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCEH1 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDCD10 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SAMD7 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SQLE 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRPF3 35 / 50 cases (70 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATAD2 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF5A2 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FNDC3B 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC34 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPL13 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTBP 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYNN 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHC3 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF139 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL22L1 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEC62 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC14A1 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC14A2 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC2A2 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC7A14 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLITRK3 129 / 185 cases (70 %) · ssm · TCGA-ESCA · largest of 2 cohorts | — | — | Esophageal Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ST8SIA5 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNIK 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN11 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COLEC10 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DEPTOR 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO32 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR160 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LOXHD1 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ME2 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MECOM 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MELTF 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MEX3C 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTAP 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NDUFB9 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLD1 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRKCI 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF165 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINI1 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SKIL 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TAF2 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TATDN1 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM212 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFSF10 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNK2 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRMT12 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBBX 128 / 185 cases (69 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3A 60 / 87 cases (69 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSPA6 60 / 87 cases (69 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ANP32E 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APH1A 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf54 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CA14 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CIART 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTXND2 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPS21 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR2B 59 / 87 cases (68 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASH1L 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | CD84 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR2A 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRLA 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRLB 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | JTB 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB13 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPS27 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF6 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC39A1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TNN 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 7 cohorts | — | — | Lung Adenocarcinoma | 7 | Observed | gdc | graph → |
| ← altered in cohorts of | TNR 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 6 cohorts | — | — | Lung Adenocarcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | UAP1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UHMK1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf56 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GABPB2 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYSMD1 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHO1 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD4 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RFX5 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMOD4 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFAIP8L2 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS72 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf189 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf226 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD48 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDR2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DUSP12 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HAX1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF8 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL6R 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ILF2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INTS3 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNJ10 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNJ9 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY9 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NOS1AP 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A13 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D1B 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF7 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPATA46 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CACNA1E 374 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 14 cohorts | — | — | Lung Adenocarcinoma | 14 | Observed | gdc | graph → |
| ← altered in cohorts of | PAPPA2 374 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 9 cohorts | — | — | Lung Adenocarcinoma | 9 | Observed | gdc | graph → |
| ← altered in cohorts of | TCHH 374 / 573 cases (65 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASTN1 373 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 6 cohorts | — | — | Lung Adenocarcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNN3 372 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | ASPM 371 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 8 cohorts | — | — | Lung Adenocarcinoma | 8 | Observed | gdc | graph → |
| ← altered in cohorts of | NUP210L 371 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAR 370 / 573 cases (65 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP8B2 370 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 4 cohorts | — | — | Lung Adenocarcinoma | 4 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL5 370 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | AQP10 369 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NPR1 369 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 4 cohorts | — | — | Lung Adenocarcinoma | 4 | Observed | gdc | graph → |
| ← altered in cohorts of | PKLR 369 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP1A4 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CRP 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECM1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GOLPH3L 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ITLN1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHDC9 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MCL1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MLLT11 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGM 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMB4 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SELENBP1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF9 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS45 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | VSIG8 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BRINP3 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 6 cohorts | — | — | Lung Adenocarcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRNB2 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CHTOP 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |